

October 16, 2023



Volition Presents Three Cancer Detection Abstracts at ESMO 2023

HENDERSON, Nev., Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology.

Dr. Jake Micallef, Chief Scientific Officer at Volition, said: "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma, and introduce what we believe to be an entirely new method for the detection of cancer."

On Saturday 21st October, Dr. Dorian Pamart, Head of Technology and Service Unit at Volition, will present a poster (205P) titled 'A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer'.

On Sunday 22nd October, Dr. Pei-Hsing Chen from National Taiwan University Hospital will present a mini oral session (133MO) titled 'Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma' in the Santander Auditorium, hall 9 at 9.30 am. The study was undertaken by Volition and the National Taiwan University Hospital and is part of a longer-term research collaboration.

In addition, Jonathan Decarpentrie, from the Research Institute for Life Sciences, University of Namur will present a poster (524P) titled 'Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma'. Volition and biotechnology company, Qualiblood have worked in collaboration with University of Namur on this latest study.

Abstract summary:

Date	Presentation Title	Presentation Number	Presentation type

Sat 21 st October	A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer'.	205P	Poster
Sun 22 nd October	Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma.	133MO	Mini oral session
Sun 22 nd October	Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma	524P	Poster

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition's technology go to: www.volition.com

About Volition

Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

For more information about Volition's Nu.Q® technology go to: www.volition.com

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor/Debra Daghish, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans,"

"aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

📄 View original content:<https://www.prnewswire.com/news-releases/volition-presents-three-cancer-detection-abstracts-at-esmo-2023-301957278.html>

SOURCE VolitionRx Limited